Active-ingredient Dossier
Sacubitril
Active-ingredient Dossier for Sacubitril (angiotensin receptor inhibitor). Australian brands, products, PBS listings, PBAC outcomes — compiled by…
- Brand: PHARMACOR
- Brand: VALTRESTO
- Brand: ENTRESTO
- Brand: ARX-SACUBITRIL/VALSARTAN
- Brand: MSN-SACUBITRIL/VALSARTAN
- Brand: OMTRALO
- Therapeutic area: Cardiology
What is
Sacubitril Sacubitril is an angiotensin receptor inhibitor.
Australian brands containing
Sacubitril — PHARMACOR — ENTRESTO — VALTRESTO — ARX-SACUBITRIL/VALSARTAN — MSN-SACUBITRIL/VALSARTAN — OMTRALO — SACUBITRIL/VALSARTAN ALPHAPHARM — SACUBITRIL/VALSARTAN LUPIN — SACUBITRIL/VALSARTAN-WGR — SACUVANCE
Therapeutic areas
Sacubitril is registered in cardiology, with 10 brands containing the ingredient on the Australian Register of Therapeutic Goods.
Sponsor landscape
Three sponsors market sacubitril in Australia: Pharmacor, Accelagen, and Novartis Pharmaceuticals.
PBS and regulatory activity
One brand containing sacubitril is PBS-listed, with the latest schedule date of 1 May 2026. In the 2024–25 financial year, government expenditure on sacubitril-containing brands reached $145,846,550.23 across 824,477 scripts. Three brands have PBAC outcomes on record, with the latest outcome dated 1 November 2024. No AusPAR has been issued for sacubitril.